Analysis of routine examinations before chemotherapy in lung cancer patients with chemotherapy-induced mylosuppression
LAI Fuzhi1 DU Yuxia2▲ ZHOU Zhibin3
1. Service Center, the Second Affiliated Hospital of Fujian Medical University
2. Department of Respiratory and Critical Care Medicine, Respiratory Medicine Center of Fujian Province
3. Department of Respiratory and Critical Care Medicine, Shishi Hospital
Abstract：Objective Analyze the routine examinations of lung cancer patients with chemotherapy-induced myelosuppression (CIM) caused by chemotherapy, and explore the clinical significance. Methods From January 2016 to December 2018, a total of 76 patients with successfully matched lung cancer who were admitted to the Department of Respiratory Diseases of the Second Affiliated Hospital of Fujian Medical University were retrospectively selected as the research objects. According to the presence or absence of bone marrow suppression after chemotherapy, they were divided into experimental group (38 cases, patients with CIM) and control group (38 cases, patients without CIM). The difference of routine examination before chemotherapy and curative effect after two cycles of chemotherapy were compared between the two groups. Results The levels of white blood cells, alkaline phosphatase, and neuraminic enolase in the experimental group before chemotherapy were lower than those in the control group, and the differences were statistically significant (P<0.05). In addition, the experimental group had better efficacy than the control group after 2 cycles of chemotherapy, and the difference was statistically significant (P<0.05). Conclusion Lower levels of white blood cells,alkaline phosphatase, and neuraminic enolase are more prone to CIM, and CIM is associated with better short-term clinical efficacy.
赖富治；杜玉霞；周志斌. 化疗引起骨髓抑制的肺癌患者的化疗前常规检查分析[J]. 中国当代医药, 2022, 29(6): 58-61.
LAI Fuzhi；DU Yuxia；ZHOU Zhibin. Analysis of routine examinations before chemotherapy in lung cancer patients with chemotherapy-induced mylosuppression. 中国当代医药, 2022, 29(6): 58-61.
Zaleska M，Szturmowicz M，Zych J，et al.The significance of the serum tumour markers as a prognostic and predictor factors in nonsmall cell lung cancer patients[J].Pneumonol Alergol Pol，2005，73（3）：270-276.
[17]
Holdenrieder S，von Pawel J，Dankelmann E，et al.Nucleosomes，ProGRP，NSE，CYFRA 21-1，and CEA in monitoring first-line chemotherapy of small cell lung cancer[J].Clin Cancer Res，2008，14（23）：7813-7821.
[18]
Netterberg I，Nielsen EI，Friberg LE，et al.Model -based prediction of myelosuppression and recovery based on frequent neutrophil monitoring[J].Cancer Chemother Pharmacol，2017，80（2）：343-353.
[19]
Cameron DA，Massie C，Kerr G，et al.Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer[J].Br J Cancer，2003，89（10）：1837-1842.
Goldstraw P，Chansky K，Chansky K，et al.The IASLC lung cancer staging project：proposals for the revision of the TNM stage groupings in the forthcoming（seventh）edition of TNM classification of malignant tumours[J].J Thorac Oncol，2007，2（8）：706-714.
[3]
Epstein RS，Aapro MS，Roy UKB，et al.Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression：Results from an Online Survey of Patients with Solid Tumors[J].Adv Rher，2020，37（8）：3606-3618.
Emin Erbaycu A，Gunduz A，Batum O，et al.Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer：an open prospective study[J].Arch Bronconeumol，2010，46（7）：364-369.
[10]
Yashiki C，Hirose T，Sugiyama T，et al.Chemotherapy-induced myelosuppression and treatment efficacy in limitedstage disease small cell lung cancer[J].Gan To Kagaku Ryoho，2010，37（2）：245-249.
[11]
Maeda T，Ueoka H，Tabata M，et al.Prognostic factors in advanced non-small cell lung cancer：elevated serum levels of neuron specific enolase indicate poor prognosis[J].Jpn J Clin Oncol，2000，30（12）：534-541.
[12]
Shibayama T，Ueoka H，Nishii K，et al.Complementary roles of pro-gastrin-releasing peptide（ProGRP）and neuron specific enolase （NSE）in diagnosis and prognosis of smallcell lung cancer（SCLC）[J].Lung Cancer，2001，32（1）：61-69.
[13]
PetroviM，IliN，BaskiD.The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer[J].Srp Arh Celok Lek，2010，138（1-2）：37-42.
[14]
Suh KJ，Keam B，Kim M，et al.Serum Neuron -Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor （EGFR）Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations [J].Clin Lung Cancer，2016，17（4）：245-252.
京公网安备 11010502046607号